Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Federal Trade Commission
Harvard Business School

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,324,779

« Back to Dashboard

Summary for Patent: 4,324,779

Title: Method for treating hypertonia with N-(2-furfuryl)-4-chloro-5-sulfamoyl-anthranilic acid and preparations thereof
Abstract:A method for treating hypertonia with a preparation of N-(2-furfuryl)-4-chloro-5-sulfamoyl-anthranilic acid having a slightly retarded release, wherein the release of the active substance in vitro, measured in the flow through-cell to Dibbern, is not more than 5% after 1 hour in a buffer solution of pH 1.5 and about 10 to at most 25% of the active substance content after a two-hour treatment in a buffer solution of pH 5.5.
Inventor(s): Dahlhausen; Gebhard (Kronberg, DE), Dibbern; Hans-Werner (Kelkheim, DE), Fulberth (Kelkheim, DE), Ross; Gerhard (Kriftel, DE)
Assignee: Hoechst Aktiengesellschaft (Frankfurt am Main, DE)
Application Number:06/077,181
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Formulation;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,324,779

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany2343218Aug 28, 1973

International Patent Family for Patent: 4,324,779

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
AustriaA694274► Subscribe
Austria344914► Subscribe
Australia7272874► Subscribe
Belgium819294► Subscribe
Canada1063024► Subscribe
Germany2343218► Subscribe
Denmark455274► Subscribe
Denmark155173► Subscribe
Egypt14662► Subscribe
Finland249774► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus